louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT06550531: Impact of Human Papillomavirus Carriage on IVF/ICSI Results (HPV AMP)
Official title: Impact of Human Papillomavirus Carriage on IVF/ICSI Results at Brest University Hospital
Study type: OBSERVATIONAL
Overall status: RECRUITING
Conditions: Human Papilloma Virus
Infertility, Female
Lead sponsor: University Hospital, Brest
Sponsor class: OTHER
First posted: 2024-08-13
Enrollment: 618
Sex: FEMALE
Minimum age (years): 25
Maximum age (years): 38
Standard ages: ADULT
Accepts healthy volunteers: no
Observational model: COHORT
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The population study is a population of infertile women who are consulting in our center of Reproduction Médicine in CHU Brest.

Brief summary: The prevalence of the papilloma virus in the general population is 12%. This virus is known to impair male fertility but its impact on female infertility remains uncertain. This is a public health problem since there is a vaccination protocol. Demonstrating the impact of the human papillomavirus on fertility would be an argument in favor of vaccination.

Detailed description: This is a single-center prospective study in the assisted reproduction center of Brest University Hospital. All new patients coming to consult will be offered participation in the study. The HPV test will be updated if it is older than 12 months. We will analyze stimulation results and pregnancy outcomes according to HPV status. Inclusions will take place over 3 years

Eligibility criteria: Inclusion Criteria:

* all etiology of infertility AMH \> ou = à 1.1 ng/ml First ou second protocol of IVF between 25 years and 37 years and 11 months

Exclusion Criteria:

Age \< 25 y Age \> ou = 38 y AMH \< 1.1 ng/ml patient under juridic protection rejection of participation

Primary outcomes:
measure: clinical pregnancy rate after fresh eSET by HPV status
timeFrame: 1 year
Secondary outcomes:
measure: IVF issues
timeFrame: 1 year
measure: Positive HPV rate
timeFrame: 1 year
Other outcomes:
Locations:
city: Brest
country: France
facility: CHRU de Brest
Study officials:
References:
Clinical trial NCT01107431: Effects of a Dietary Supplement Containing L-Arabinose and Trivalent Patented Food-source of Chromium on Blood Glucose and Insulin
Official title: A Combination of L-Arabinose and Chromium Lowers Circulating Glucose and Insulin Levels After Acute Oral Sucrose Challenge
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Pre-diabetes
Keywords: glucose
insulin
L-arabinose
Chromium
Lead sponsor: Integrative Health Technologies, Inc.
Sponsor class: NETWORK
First posted: 2010-04-21
Enrollment: 70
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: PREVENTION

Brief summary: This study was designed to examine changes in capillary blood glucose and venous insulin levels after a 70 gram oral sucrose challenge with and without simultaneous consumption of a dietary supplement containing L-Arabinose and a patented version of chromium (LA-Cr).

Detailed description: This study concluded that consumption of the LA-Cr supplement in conjunction with a 70-gram sucrose challenge led to a significant reduction of capillary blood glucose and venous insulin as compared to the sucrose challenge without the LA-Cr supplement. This finding may provide an important tool to reduce the adverse effects associated with elevated glucose and insulin levels.

Eligibility criteria: Inclusion Criteria:

* All study subjects were required to contact their family physician to ensure they had no medical conditions that would preclude their participation.

Exclusion Criteria:

* Diabetics, and
* Those not approved by their physicians.

Primary outcomes:
measure: Fasting Blood Glucose
timeFrame: Every 15 to 30 minutes
Secondary outcomes:
measure: Fasting Blood Insulin Levels
timeFrame: Every 30 minutes
Other outcomes:
Locations:
city: San Antonio
country: United States
facility: Integrative Health Technologies
state: Texas
Study officials:
affiliation: Integrative Health Technologies
name: Gilbert R Kaats, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Georgetown University
name: Harry G Preuss, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Kaats GR, Keith SC, Keith PL, Leckie RB, Perricone NV, Preuss HG. A combination of l-arabinose and chromium lowers circulating glucose and insulin levels after an acute oral sucrose challenge. Nutr J. 2011 May 6;10:42. doi: 10.1186/1475-2891-10-42.
Clinical trial NCT03990831: Frontal Lobe Oxyhemoglobin Levels in Patients With Lower Extremity Burns Assessed Using a fNIRS
Official title: Frontal Lobe Oxyhemoglobin Levels in Patients With Lower Extremity Burns Assessed Using a Functional Near-Infrared Spectroscopy Device During Usual Walking: A Pilot Study
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Walking
Keywords: Burn
Near-infrared spectroscopy (NIRS)
Lead sponsor: Hangang Sacred Heart Hospital
Sponsor class: OTHER
Collaborators: name: National Research Foundation of Korea
First posted: 2019-06-19
Enrollment: 36
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: patients with lower extremity burn : 15 patients patients with upper extremity burn : 10 patients healthy controls : 11
Primary purpose: DIAGNOSTIC

Brief summary: Investigators investigate the patterns of cortical activation using the NIRST in patients with peripheral neurological injury caused by lower extremity burns.

Detailed description: Understanding the mechanisms associated with locomotor networks may be of benefit for rehabilitation of burn victims with neurological locomotor deficits. However, the effects of peripheral neurological injury on locomotor network remains unknown. A wearable functional near-infrared spectroscopy (fNIRS) device has been developed for studying cortical hemodynamics. Changes in cortical activity has not previously been documented in patients with burn injury.

Investigators assessed 15 patients with lower extremity burns and 11 healthy controls.

Investigators measured walking-related cortical activity using an fNIRS device at baseline and during usual walking.

Cortical activity was measured by evaluating relative changes in oxyhemoglobin level. The NIRST Analysis Tool v2.1 was utilized to analyze fNIRS data in a MATLAB environment.

Eligibility criteria: Inclusion Criteria:

* burn patients with lower extremity or upper extremity thermal injury
* patients who could walk unassisted for at least 5min.

Exclusion Criteria:

* patients with critical systemic conditions
* severe cognitive impairment
* had severe pain
* unable to walk.

Primary outcomes:
measure: oxygenated hemoglobin (HbO2) of the prefrontal regions,
timeFrame: 5 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Seoul
country: Korea, Republic of
facility: Hangang Sacred Heart Hospital
state: Yeongdeungpo-Ku
Study officials:
affiliation: Hangang Sacred Heart Hospital
name: Cheong Hoon Seo, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
citation: Al-Yahya E, Johansen-Berg H, Kischka U, Zarei M, Cockburn J, Dawes H. Prefrontal Cortex Activation While Walking Under Dual-Task Conditions in Stroke: A Multimodal Imaging Study. Neurorehabil Neural Repair. 2016 Jul;30(6):591-9. doi: 10.1177/1545968315613864. Epub 2015 Oct 21.
citation: Kim HY, Kim EJ, You JSH. Adaptive locomotor network activation during randomized walking speeds using functional near-infrared spectroscopy. Technol Health Care. 2017 Jul 20;25(S1):93-98. doi: 10.3233/THC-171310.
Clinical trial NCT04327531: Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study
Official title: Evaluation of Covid 19 Knowledge Anxiety and Expectation Levels of Turkish Physicians, Survey Study
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: COVID-19
Physician-Patient Relations
Keywords: covid-19
turkish physicians
Lead sponsor: Kanuni Sultan Suleyman Training and Research Hospital
Sponsor class: OTHER
First posted: 2020-03-31
Enrollment: 200
Sex: ALL
Minimum age (years): 25
Maximum age (years): 55
Standard ages: ADULT
Accepts healthy volunteers: yes
Observational model: ECOLOGIC_OR_COMMUNITY
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: turkish physicians, who work active in pandemic hospital

Brief summary: It is aimed to measure the general health information of Turkish physicians about covid 19 pandemic, to evaluate anxiety levels and to evaluate future expectations in this period.


Eligibility criteria: Inclusion Criteria:

* turkish physicians
* work active in pandemic hospital

Exclusion Criteria:

* work in another country
* retired physicians

Primary outcomes:
measure: Evaluation of covid-19 knowledge level of turkish physicians
timeFrame: 1 month
Secondary outcomes:
measure: what they think about the future
timeFrame: 1 month
Other outcomes:
Locations:
city: Istanbul
country: Turkey
facility: Pinar Yalcin Bahat
state: İ̇stanbul
Study officials:
References:
citation: Yalcin Bahat P, Aldikactioglu Talmac M, Bestel A, Topbas Selcuki NF, Karadeniz O, Polat I. Evaluating the effects of the COVID-19 pandemic on the physical and mental well-being of obstetricians and gynecologists in Turkey. Int J Gynaecol Obstet. 2020 Oct;151(1):67-73. doi: 10.1002/ijgo.13287. Epub 2020 Aug 11.
Clinical trial NCT02025231: Image Guided Reirradiation of High-grade Glioma
Official title: Image Guided Reirradiation of High-grade Glioma - a Phase I/II Dose Escalation Study
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE1
PHASE2
Conditions: Malignant Glioma
Glioblastoma
Keywords: reirradiation
recurrent glioma
positron emission tomography
amino acid tracer
Lead sponsor: Rigshospitalet, Denmark
Sponsor class: OTHER
Collaborators: name: Danish Center for Interventional Research in Radiation Oncology (CIRRO)
First posted: 2013-12-31
Enrollment: 31
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of the study is to evaluate the short- and long term toxicity of radiotherapy to patients with recurrent high-grade glioma who have previously received radiotherapy and to determine the best dose and treatment regimen. Positron emission tomography (PET) using an amino acid tracer, 18-fluoro-ethyltyrosine (18F-FET), is used for target delineation.The study examines, in four sequential treatment groups, the effect of dose, hypofractionation and treatment volume on toxicity. Upon completion of the phase I part, the study progresses to phase II where the best dose- and treatment regimen will be chosen for treatment.


Eligibility criteria: Inclusion Criteria:

* recurrent high-grade glioma
* previous focal radiotherapy for high-grade glioma
* no standard treatment options available/indicated
* ECOG (Eastern Cooperative Oncology Group) performance status 0 or 1 or 2
* life expectancy \> 3 months
* hemoglobin value \> 6 mmol/l (transfusion permitted)
* able to understand oral and written Danish

Exclusion Criteria:

* disseminated recurrent disease
* infection or wound dehiscence or other pathological condition in meninges/skull/scalp
* symptoms of elevated intracranial pressure
* very early recurrence following primary radiotherapy (\< or equal to 3 months)
* contraindications to magnetic resonance imaging (MRI) or positron emission tomography (PET)
* other previous radiotherapy to the brain than primary course of irradiation

Primary outcomes:
measure: Toxicity
timeFrame: One year
measure: Diagnostic precision of 18F-FET-PET imaging in recurrent high-grade glioma
timeFrame: Approximately one to two weeks prior to radiotherapy
measure: Time to neurocognitive decline
timeFrame: Up to one year
measure: Time to progression
timeFrame: Up to one year
Secondary outcomes:
measure: Value of 18F-FET-PET in reirradiation of high-grade glioma
timeFrame: One year
measure: Objective response rate
timeFrame: Up to one year
Other outcomes:
Locations:
city: Copenhagen
country: Denmark
facility: Department of Radiation Oncology, Rigshospitalet
city: Lund
country: Sweden
facility: Skånes universitetssjukhus
Study officials:
affiliation: Department of Radiation Oncology, Rigshospitalet, Blegdamsvej 9, 2100 Copenhagen Ø
name: Svend Aage Engelholm, MD
role: STUDY_CHAIR
References:
Clinical trial NCT03394131: ُEfficacy of Insulin Versus Hyalase Hydro-dissection of Median Nerve in Rheumatoid Arthritis Patients
Official title: Treatment of Carpal Tunnel in Rheumatoid Arthritis
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Treatment Resistant Carpal Tunnel in RA Patients
Lead sponsor: Assiut University
Sponsor class: OTHER
First posted: 2018-01-09
Enrollment: 90
Sex: ALL
Minimum age (years): 20
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy in Rheumatoid arthritis patients proved by nerve conduction studies and ultrasound parameters, this study aims to evaluate the effect of hydro-dissection using insulin versus hyalase versus saline, ultrasounic guided as an effective treatment

Detailed description: Carpal tunnel syndrome (CTS) is a common peripheral entrapment neuropathy in Rheumatoid arthritis patients proved by nerve conduction studies and ultrasound parameters, this study aims to evaluate the effect of hydro-dissection of median nerve inside CT twice injections with interval 2 weeks using insulin and 10 cc saline versus hyalase and 10 cc saline versus 10 cc saline, ultrasounic guided as an effective treatment of CT

Eligibility criteria: Inclusion Criteria:

* Rheumatoid arthritis in remission

Exclusion Criteria:

* active Rheumatoid arthritis

Primary outcomes:
measure: pain intensity
timeFrame: 6 months
Secondary outcomes:
measure: nerve conduction
timeFrame: 6 months
measure: ultrasound
timeFrame: 6 months
Other outcomes:
Locations:
city: Assiut
country: Egypt
facility: Manal Hassanien
state: Assuit
Study officials:
affiliation: Assiut University
name: Manal Hassanien, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00852631: Seroquel XR in Adults With Schizophrenia
Official title: Open-label Multicentre Study on Efficacy and Safety of Oral Quetiapine (Seroquel XR) in Adults With Schizophrenia
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE3
Conditions: Schizophrenia
Keywords: Quetiapine efficacy in schizophrenia
Lead sponsor: AstraZeneca
Sponsor class: INDUSTRY
First posted: 2009-02-27
Enrollment: 28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to evaluate the efficacy of Seroquel XR in schizophrenia patients with acute worsening symptoms. Consequently, to assess whether the study drug is safe and acceptable on the daily dose basis, orally given, up to 600 mg once a day for 42 days.


Eligibility criteria: Inclusion Criteria:

* Patient meets the DSM-IV criteria for schizophrenia
* Patient has a PANSS total score ≥ 70 at baseline
* Patient has a CGI-S score of ≥ 4(moderately ill) at baseline
* Patient is healthy on the basis of physical examination and vital signs at baseline

Exclusion Criteria:

* Positive urine drug screen for Opiates, amphetamine, barbiturate, cocaine, cannabis, or ecstasy abuse
* Has history of neuroleptic malignant syndrome, seropositive for anti-HIV, hepatitis B or C virus antigen
* Patient with unstable or inadequately treated Diabetes Mellitus
* Use of potent cytochrome P450 inhibitors or inducer within 14 days before baseline

Primary outcomes:
measure: Change in Positive and Negative Syndrome Scale (PANSS) Total Score
timeFrame: From Day 1 (baseline) to Day 42
Secondary outcomes:
measure: Change in Clinical Global Impression - Severity of Illness (CGI-S) Score
timeFrame: From Day 1 (Baseline) to Day 42
measure: Clinical Global Impression - Severity of Illness (CGI-S) Score
timeFrame: Day 14
Other outcomes:
Locations:
city: Bangkok
country: Thailand
facility: Research Site
city: Chiang Mai
country: Thailand
facility: Research Site
city: Songkla
country: Thailand
facility: Research Site
Study officials:
affiliation: Phramongkutklao Hospital, Bangkok, Thailand
name: Thawatchai Leelahanaj, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03650231: Comparison of Technics for Determination of Epstein-Barr Virus Serological Diagnosis
Official title: Comparison of Abbott Architect®, Siemens Immulite®, and Diasorin Liaison® for Determination of Epstein-Barr Virus Serological Diagnosis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: EBV
Keywords: Epstein-barr virus
infectious mononucleosis
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2018-08-28
Enrollment: 91
Sex: ALL
Minimum age (years): 3
Maximum age (years): 82
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: RETROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: 91 samples collected between 2014 and 2015 for which EBV diagnosis was requested. The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). The median age of patients was 34 years (mean: 38 years, range: 3-82 year) with a sex ratio of 50%. Sixteen of the 91 samples concerned children (\<15 years)

Brief summary: This study compared the performance of three automated immunoassays, Architect (Abbott), Immulite (Siemens) and Liaison (Diasorin), for Epstein-Barr virus (EBV) serology. Ninety-one serum samples collected in Amiens University Hospital were analyzed for the presence of Viral Capsid Antigen (VCA) IgG and IgM and Epstein-Barr Nuclear Antigen (EBNA) IgG. The agreement between the three assays was calculated for each marker individually and for determination of the EBV profile, based on interpretation of the combination of these three EBV markers.

Detailed description: This retrospective study was conducted on 91 samples collected between 2014 and 2015 for which EBV diagnosis was requested. The serological diagnosis of EBV infection was performed in the Amiens University Hospital virology laboratory (France). The median age of patients was 34 years (mean: 38 years, range: 3-82 year) with a sex ratio of 50%. Sixteen of the 91 samples concerned children (\<15 years).

This study compared the performance of three automated immunoassays, Architect (Abbott), Immulite (Siemens) and Liaison (Diasorin), for Epstein-Barr virus (EBV) serology. Ninety-one serum samples collected in Amiens University Hospital were analyzed for the presence of Viral Capsid Antigen (VCA) IgG and IgM and Epstein-Barr Nuclear Antigen (EBNA) IgG. The agreement between the three assays was calculated for each marker individually and for determination of the EBV profile, based on interpretation of the combination of these three EBV markers.

Eligibility criteria: Inclusion Criteria:

* Patients with EBV diagnosis
* Age between 3 and 82 years

Exclusion Criteria:

* Patient \<3 years
* Patient \> 82 years

Primary outcomes:
measure: Capacity of the three assays to detect VCA IgM
timeFrame: 2years
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: CHU AMIENS
name: Sandrine Castelain, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT01331031: Parafunctional Habits and Temporomandibular Disorder in Adolescents
Official title: Association Between Parafunctional Habits and Signs and Symptoms Temporomandibular Disorder in Adolescents
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Temporomandibular Disorder
Adolescent Behavior
Keywords: temporomandibular disorder
adolescents
Lead sponsor: University of Nove de Julho
Sponsor class: OTHER
First posted: 2011-04-07
Enrollment: 244
Sex: ALL
Minimum age (years): 10
Maximum age (years): 20
Standard ages: CHILD
ADULT
Accepts healthy volunteers: yes
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: 244 adolescents between 10 and 20 years of age and enrolled in a municipal school system.

Brief summary: The disorders that affect the temporomandibular joint (TMJ) are responsible for the diverse symptoms. Objective: To evaluate whether or not the relationship between signs or symptoms of TMD and presence of harmful habits. The investigators evaluated 244 adolescents enrolled in public school . The investigators used the questionnaire for selection of orofacial pain and temporomandibular disorders, recommended by American Academy of Orofacial Pain to assess the presence or absence of signs and symptoms of TMD.

Detailed description: For the assessment of signs and symptoms of TMD and parafunctional habits, 244 adolescents between 10 and 20 years of age and enrolled in a municipal school system were analyzed. The participants were submitted to the self-explanatory questionnaire for screening recommended by the American Academy of Orofacial Pain for the determination of orofacial pain and TMD. This questionnaire is made up of ten guided questions with yes or no responses to the most frequent signs and symptoms of orofacial pain and TMD. According to the Academy, three or more affirmative responses are an indication of TMD. Patient history and a detailed clinical exam were performed for the assessment of the presence or absence of parafunctional habits.

The frequency of signs and symptoms was analyzed and the data were described based on gender and age. The SPSS 12.0 program was used for the statistical analysis and the data were treated using the chi-square test.

Eligibility criteria: Inclusion Criteria:

* age: 10 to 20 years old

Exclusion Criteria:

* no signing a term of informed consent

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Sao Paulo
country: Brazil
facility: Nove de Julho University
Study officials:
affiliation: University of Nove de Julho
name: Lara Motta, Ms
role: PRINCIPAL_INVESTIGATOR
References: